Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study

doi:10.1016/j.ejca.2022.06.059

	Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study
	Wang, Wenxian 1,2; Lin, Gen 3; Guan, Yelan 2; Zhang, Yuxin 4; Xu, Chunwei 5; Wang, Qian 6; Wang, Dong 5; Jiang, Zhansheng 7; Cai, Jing 8; Lou, Guangyuan 1,2
刊名	EUROPEAN JOURNAL OF CANCER
	2022-10-01
卷号	174
关键词	Thymic carcinoma Immunotherapy PD-1 Efficacy Immune-related adverse events
ISSN号	0959-8049
DOI	10.1016/j.ejca.2022.06.059
通讯作者	Song, Zhengbo(zheng_bo_song@163.com) ; Zhang, Yongchang(zhangyongchang@csu.edu.cn)
英文摘要	Background: Immunotherapy has demonstrated good efficacy and survival out-comes in solid tumours. However, efficacy data for immune checkpoint inhibitors (ICIs) in advanced thymic carcinoma are lacking. The present study aimed to assess the activity of ICIs in advanced thymic carcinoma.Methods: A multicentre retrospective study was conducted to explore the efficacy and safety of ICIs for advanced thymic carcinoma. Objective response rate (ORR), progression-free sur-vival (PFS), overall survival, and immune-related adverse events (irAEs) were analysed. In addition, factors independently associated with treatment efficacy and survival outcomes were evaluated.Results: A total of 77 patients with advanced thymic carcinoma were enrolled between March 2016 and September 2021. The ORR was existing the difference between ICIs monotherapy (n = 23) and ICIs combined with chemotherapy (n = 54) (17.4% versus 44.4%, P = 0.024). The ICIs combination treatments were associated with better median PFS (mPFS) compared to ICIs monotherapy (12.7 months versus 2.1 months, P < 0.001). Notably, liver or brain metastasis was a poor prognostic factor of mPFS (1.8 months versus 3.5 months, P = 0.012) in the ICIs monotherapy group. In addition, mPFS for the first-line treatment (n = 27) was longer than that for ICIs as the second-or posterior-line treatment (n = 50) (P < 0.001). The incidence of irAEs was 54.5% (42/77) in the 77 enrolled patients. The inci-dence of grade 3-4 irAE was 15.6% (12/77).Conclusions: Immunotherapy is effective in advanced thymic carcinoma, especially for combi-nation with chemotherapy showed promising antitumour activity, which indicates worthy of combination treatment strategy for further study. IrAEs also require close monitoring and management. 2022 Elsevier Ltd. All rights reserved.
WOS关键词	PHASE-II ; SINGLE-CENTER ; CARBOPLATIN ; THYMOMA ; PACLITAXEL ; CHEMOTHERAPY ; NIVOLUMAB ; ARM
WOS研究方向	Oncology
语种	英语
出版者	ELSEVIER SCI LTD
WOS记录号	WOS:000880826800003
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/130150]
专题	中国科学院合肥物质科学研究院
通讯作者	Song, Zhengbo; Zhang, Yongchang
作者单位	1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China 3.Fujian Med Univ, Fujian Canc Hosp, Canc Hosp, Dept Thorac Oncol, Fuzhou, Peoples R China 4.Hangzhou Canc Hosp, Dept Radiotherapy, Hangzhou, Peoples R China 5.Nanjing Univ, Jinling Hosp, Sch Med, Dept Resp Med, Nanjing, Peoples R China 6.Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Nanjing, Peoples R China 7.Tianjin Med Univ, Natl Clin Res Ctr Canc, Canc Inst & Hosp, Dept Integrat Oncol,Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China 8.Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Peoples R China 9.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Med Oncol,Lung Canc & Gastroi, Changsha, Peoples R China 10.Chinese Acad Sci Univ, Canc Hosp, Zhejiang Canc Hosp, Dept Med Oncol, 1 Banshan East St, Hangzhou 310022, Peoples R China
推荐引用方式 GB/T 7714	Wang, Wenxian,Lin, Gen,Guan, Yelan,et al. Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study[J]. EUROPEAN JOURNAL OF CANCER,2022,174.
APA	Wang, Wenxian.,Lin, Gen.,Guan, Yelan.,Zhang, Yuxin.,Xu, Chunwei.,...&Zhang, Yongchang.(2022).Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study.EUROPEAN JOURNAL OF CANCER,174.
MLA	Wang, Wenxian,et al."Treatment outcomes and prognosis of immune checkpoint inhibitors therapy in patients with advanced thymic carcinoma: A multicentre retrospective study".EUROPEAN JOURNAL OF CANCER 174(2022).